Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.68

0.11 (1.97%)

16:20
08/10/17
08/10
16:20
08/10/17
16:20

TherapeuticsMD receives letter from FDA regarding TX-004HR

TherapeuticsMD announced a regulatory update regarding the New Drug Application, or NDA, for TX-004HR, the company's investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse, or dyspareunia, a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. The Company has received a formal General Advice Letter from the FDA stating that an initial review of this information has been completed and requesting that the Company submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18 including the safety data from a very large, observational study of long-term, real-world users of vaginal estrogens that is pending publication. The FDA requested approximately six weeks to perform a comprehensive review of these data and has requested a meeting with the Company to discuss the outcome of this review. A tentative meeting date of November 3 has been set by the Agency. At this meeting, the Company expects to learn if this additional endometrial safety data addresses the lack of long-term safety identified in the CRL. The Company currently plans to re-submit the NDA for TX-004HR shortly thereafter.

TXMD TherapeuticsMD
$5.68

0.11 (1.97%)

08/04/17
OPCO
08/04/17
NO CHANGE
Target $10
OPCO
Outperform
TherapeuticsMD talks with FDA increasingly collaborative, says Oppenheimer
After TherapeuticsMD provided an update on the regulatory process for both TX-004HR and TX-001HR, Oppenheimer analyst Jay Olson says he believes the narrative between the company and the FDA has become "more collaborative." This suggests next week's potential update on TX-004HR could be favorable, Olson tells investors in a research note. The analyst keeps an Outperform rating on TherapeuticsMD with a $10 price target.
07/21/17
DBAB
07/21/17
INITIATION
Target $10
DBAB
Buy
TherapeuticsMD initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Esther Rajavelu started TherapeuticsMD with a Buy rating and $10 price target. Current trading levels do not fully reflect the TX-001 market opportunity and provide an attractive entry point for investors, the analyst contends. Rajavelu sees upside from current trading levels regardless of the regulatory outcome for TX-004.
07/17/17
STFL
07/17/17
NO CHANGE
Target $20
STFL
Buy
Stifel sees high likelihood FDA lets TherapeuticsMD do post-marketing study
Stifel analyst Annabel Samimy said a lack of clarity is pressuring TherapeuticsMD shares after the company provided a regulatory update on the status of its New Drug Application for TX-004HR, but he thinks there is a high likelihood that the FDA will allow the company to proceed with a post-marketing safety study. Samimy, who still expects a resubmission within weeks and FDA action within two months, keeps a Buy rating and $20 price target on TherapeuticsMD.
07/11/17
OPCO
07/11/17
UPGRADE
Target $10
OPCO
Outperform
TherapeuticsMD upgraded ahead of FDA meeting update at Oppenheimer
Oppenheimer analyst Jay Olson upgraded TherapeuticsMD to Outperform from Perform with a $10 price target. The stock closed yesterday down 21c to $4.80. Details of the company's meeting with the FDA are likely to be announced around July 14 and there is a "reasonable probability" of positive news, Olson tells investors in a research note. Evidence supports a scenario where TherapeuticsMD is likely to resubmit TX-004HR by July 31 with a potential FDA approval by September 29 in the best case, the analyst adds. He assigns a 60% probability to this scenario.

TODAY'S FREE FLY STORIES

GDX

Market Vector Gold Miners

$23.09

-0.22 (-0.94%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$122.21

-0.55 (-0.45%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRAM

Everspin Technologies

$15.22

0.3 (2.01%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Hot Stocks
Everspin Technologies names Kevin Conley as CEO, effective September 1 »

Everspin Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

NUGT

Direxion Gold Miners Bull

$32.79

-0.86 (-2.56%)

05:57
08/23/17
08/23
05:57
08/23/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.22

-0.58 (-3.09%)

05:56
08/23/17
08/23
05:56
08/23/17
05:56
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$26.31

0.61 (2.37%)

05:56
08/23/17
08/23
05:56
08/23/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.10

1.74 (2.98%)

05:56
08/23/17
08/23
05:56
08/23/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$47.36

-3.72 (-7.28%)

05:55
08/23/17
08/23
05:55
08/23/17
05:55
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$82.37

5.27 (6.84%)

05:55
08/23/17
08/23
05:55
08/23/17
05:55
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$16.79

-2.75 (-14.07%)

05:54
08/23/17
08/23
05:54
08/23/17
05:54
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$78.87

5.4 (7.35%)

05:54
08/23/17
08/23
05:54
08/23/17
05:54
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$9.77

0.06 (0.62%)

05:54
08/23/17
08/23
05:54
08/23/17
05:54
Technical Analysis
United States Oil Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$29.34

0.25 (0.86%)

05:53
08/23/17
08/23
05:53
08/23/17
05:53
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$25.16

0.58 (2.36%)

05:52
08/23/17
08/23
05:52
08/23/17
05:52
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$12.14

-0.29 (-2.33%)

05:52
08/23/17
08/23
05:52
08/23/17
05:52
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$39.33

0.58 (1.50%)

05:52
08/23/17
08/23
05:52
08/23/17
05:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$66.49

0.32 (0.48%)

05:51
08/23/17
08/23
05:51
08/23/17
05:51
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$37.02

0.17 (0.46%)

05:51
08/23/17
08/23
05:51
08/23/17
05:51
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.44

-0.12 (-0.51%)

05:51
08/23/17
08/23
05:51
08/23/17
05:51
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.92

0.36 (0.41%)

05:50
08/23/17
08/23
05:50
08/23/17
05:50
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.70

-0.12 (-0.10%)

05:50
08/23/17
08/23
05:50
08/23/17
05:50
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$126.44

-0.49 (-0.39%)

05:50
08/23/17
08/23
05:50
08/23/17
05:50
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

05:49
08/23/17
08/23
05:49
08/23/17
05:49
Technical Analysis
iShares Silver Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USLV

VelocityShares 3x Long Silver ETN

$12.37

-0.01 (-0.08%)

05:49
08/23/17
08/23
05:49
08/23/17
05:49
Technical Analysis
VelocityShares 3x Long Silver ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYR

DJ US Real Estate Index Fund

$79.82

-0.07 (-0.09%)

05:48
08/23/17
08/23
05:48
08/23/17
05:48
Technical Analysis
DJ US Real Estate Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.